CROI 2024

CROI 2024
March 03-06, 2024
Denver, Colorado - USA

Conference on Retroviruses and Opportunistic Infections - 31st Annual.

Explore more information for Gilead HIV / AIDS therapies
Results (20)

Bone Mineral Density in Children With HIV-1 Receiving TAF-Based Antiretroviral Therapy

Longitudinal Analysis of Preexisting Resistance-Associated Mutations Prior to B/F/TAF Switch

Phase 2 Study of Switch to Daily BIC + LEN in Individuals on a Multitablet HIV Treatment Regimen​

Antiviral Activity, Safety, and Pharmacokinetics of GS-1720: A Novel Weekly Oral InSTI

Preclinical Characterization of GS-5894, A Potent NNRTI With Once-Weekly Oral Dosing Potential

Efficacy and Safety of Weekly Islatravir Plus Lenacapavir in PWH at 24 Weeks: A Phase II Study​

Characteristics and Outcomes of Kidney Transplant Patients Hospitalized for COVID-19 in the United States

Type I IFN Signaling and Regulation in Vesatolimod-Treated Virally Suppressed Adults With HIV-1

PrEP Non-Persistence and New HIV Diagnoses: A Real-World Analysis of >120,000 People Prescribed PrEP

Efficacy and Safety of Bulevirtide 2 mg or 10 mg for 96 Weeks in Chronic Hepatitis Delta, Including in 2 PatientsWith HIV/Hepatitis B Virus/Hepatitis Delta Virus

Discovery of GS-9770 - A Novel Unboosted Once Daily Oral HIV-Protease Inhibitor

Lenacapavir Plus bNAbs for People With HIV and Sensitivity to Either Teropavimab or Zinlirvimab

Impact of HIV-1 Capsid Polymorphisms on Viral Fitness and Susceptibility to Lenacapavir

Racial and Ethnic Disparities in COVID-19 Treatments in the United States

Remdesivir + Dexamethasone Versus Dexamethasone For the Treatment of COVID-19: Real-World Study in the US

Remdesivir Reduces Mortality in Immunocompromised Patients Hospitalised for COVID-19 During Omicron

Effect of Remdesivir on Post-COVID Conditions Among Individuals Hospitalized With COVID-19 By Age

Phenotyopic Characterization of Replication-Impaired Lenacapavir-Resistant HIV Clinical Isolates

Factors Associated With HBV Response to B/F/TAF Versus DTG + F/TDF at Week 96 in People With Both HIV-1 and HBV

Lenacapavir Efficacy in CAPELLA Patients With No Fully Active Agents in Optimized Background Regimen